US: AKBLF - ALK-Abelló A/S

Rentabilité sur six mois: +46.12%

Calendrier des promotions ALK-Abelló A/S

Calendrier avancé Graphique simple
Financial Markets by TradingView

À propos de l'entreprise

ALK-Abelló A/S operates as an allergy solutions company in Europe, North America, and internationally. Its product portfolio includes GRAZAX/GRASTEK, RAGWITEK/RAGWIZAX, ACARIZAX/ODACTRA, MITICURE, CEDARCURE, and ITULAZAX/ITULATEK for treatment of allergic rhinitis and allergic asthma. The company offers allergy immunotherapy products in the form of injections, sublingual drops, and tablets for the treatment of various allergies, including grass, ragweed, house dust mite, Japanese cedar, tree, and food.

Plus de détails
It also provides consumer healthcare solution, which include Digital eco-system, a platform which connect and engages with allergy sufferers in the disease journey through tools and e-commerce offerings that supports, guidance and relief, and smoothing the path to allergy immunotherapy treatment. In addition, the company offers diagnostic allergy solutions through testing by skin prick test or blood test; and emergency treatment, such as intra-muscular injection of adrenaline for the treatment of acute life-threatening allergic reactions, including Anaphylaxis. The company has a collaboration with Torii Pharmaceutical Co., Ltd. to develop, market and distribute allergy immunotherapy tablet for the treatment of grass pollen allergy. ALK-Abelló A/S was founded in 1923 and is headquartered in Horsholm, Denmark.
Ajouter à la liste de comparaison
Ajouter à la liste de surveillance
Ajouter au portefeuille
Ajouter un avis de prix

Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета dkk
Сайт https://www.alk.net
Цена ао 27.03
Changement de prix par jour: 0% (27.0328)
Changement de prix par semaine: +9.89% (24.6)
Changement de prix par mois: +24.69% (21.68)
Changement de prix sur 3 mois: +33.17% (20.3)
Changement de prix sur six mois: +46.12% (18.5)
Changement de prix par an: +137.13% (11.4)
Evolution du prix sur 3 ans: -94.45% (487)
Evolution du prix sur 5 ans: -87.8% (221.5)
Evolution des prix sur 10 ans: 0% (27.0328)
Evolution des prix depuis le début de l'année: +137.13% (11.4)
Tous les paramètres

Sous-estimation

Nom Signification Grade
P/S 0 0
P/BV 0 0
P/E 0 0
EV/EBITDA 0 0
Total: 2.5

Efficacité

Nom Signification Grade
ROA, % 0 0
ROE, % 0 0
Total: 0

Dividendes

Nom Signification Grade
Div yield, % 0 0
DSI 1 10
Total: 1.61

Devoir

Nom Signification Grade
Debt/EBITDA 0 10
Total: 10

Impulsion de croissance

Nom Signification Grade
Rentabilité Revenue, % 47.34 6
Rentabilité Ebitda, % 268.55 10
Rentabilité EPS, % -833.33 0
Total: 3.2
Plus de détails

Superviseur Titre d'emploi Paiement Année de naissance
Mr. Claus Steensen Solje Executive VP, CFO & Member of Management Board 1972 (52 année)
Mr. Søren Daniel Niegel Executive VP of Commercial Operations & Member of Management Board 1971 (53 année)
Dr. Henriette Mersebach Executive VP Research & Development & Member of Management Board 1971 (53 année)
Ms. Katja Barnkob Thalund Project Director of Global CMC Development & Employee-elected Director 1969 (55 années)
Ms. Lise Lund Maerkedahl Project Director of Global Research & Employee-elected Director 1967 (57 années)
Mr. Peter Halling President & CEO 1977 (47 années)
Mr. Per Plotnikof VP of Corporate Communications, Investor Relations & Strategic Planning and Head of IR
Prof. Hendrik Kees Kam Nolte M.D., Ph.D. Senior Vice President of Research & Development - North America and International Markets
Mr. Christian G. Houghton Head of Product Supply
Mr. Peter Sejer Andersen Senior Vice President of Global Research & Drug Discovery

Adresse: Denmark, Horsholm, BOege AllE 6-8 - ouvrir dans Google Maps, ouvrir les cartes Yandex
Site web: https://www.alk.net